Citizens Jmp Lowers Altimmune (NASDAQ:ALT) Price Target to $11.00

Altimmune (NASDAQ:ALT) had its price target dropped by research analysts at Citizens Jmp from $14.00 to $11.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp’s price objective suggests a potential upside of 272.25% from the stock’s previous close.

ALT has been the topic of several other research reports. Barclays started coverage on Altimmune in a research note on Tuesday, January 27th. They set an “overweight” rating and a $20.00 price objective on the stock. HC Wainwright lifted their target price on Altimmune from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a report on Friday, March 27th. Truist Financial assumed coverage on Altimmune in a research note on Wednesday, March 18th. They set a “buy” rating and a $12.00 price objective on the stock. Finally, Wall Street Zen downgraded shares of Altimmune from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Altimmune presently has an average rating of “Moderate Buy” and an average price target of $17.50.

Altimmune Stock Down 2.2%

ALT stock traded down $0.07 during mid-day trading on Thursday, hitting $2.96. 447,378 shares of the company were exchanged, compared to its average volume of 4,493,037. The firm has a fifty day simple moving average of $3.31 and a 200 day simple moving average of $4.12. The company has a market capitalization of $384.45 million, a PE ratio of -2.94 and a beta of 0.18. Altimmune has a twelve month low of $2.56 and a twelve month high of $7.73. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.15.

Altimmune (NASDAQ:ALT) last issued its earnings results on Wednesday, May 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 49.35%. On average, research analysts forecast that Altimmune will post -1 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jerome Benedict Durso bought 20,000 shares of the stock in a transaction dated Friday, March 6th. The stock was bought at an average cost of $3.54 per share, with a total value of $70,800.00. Following the completion of the acquisition, the chief executive officer owned 32,500 shares of the company’s stock, valued at $115,050. This trade represents a 160.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cetera Investment Advisers grew its stake in Altimmune by 19.4% during the 1st quarter. Cetera Investment Advisers now owns 35,453 shares of the company’s stock worth $109,000 after buying an additional 5,766 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Altimmune by 268.7% in the first quarter. Dimensional Fund Advisors LP now owns 1,045,926 shares of the company’s stock worth $3,221,000 after buying an additional 762,223 shares during the period. Bank of New York Mellon Corp lifted its stake in Altimmune by 16.7% in the first quarter. Bank of New York Mellon Corp now owns 413,503 shares of the company’s stock valued at $1,274,000 after buying an additional 59,302 shares during the last quarter. Beirne Wealth Consulting Services LLC lifted its stake in Altimmune by 9.4% in the first quarter. Beirne Wealth Consulting Services LLC now owns 411,858 shares of the company’s stock valued at $1,269,000 after buying an additional 35,400 shares during the last quarter. Finally, Hsbc Holdings PLC boosted its holdings in shares of Altimmune by 16.7% during the first quarter. Hsbc Holdings PLC now owns 154,365 shares of the company’s stock valued at $476,000 after acquiring an additional 22,144 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.